Process for preparing 5-[(R)-2-(5,6-diethyl-indian-2-ylamino)-1 -hydroxyethyl)-8-hydroxy-(1H)-quinolin-2-one salt, useful as an adrenoceptor agonist

Details for Australian Patent Application No. 2004215647 (hide)

Owner Novartis AG

Inventors Vogel, Caspar; Lohse, Olivier

Agent Davies Collison Cave

Pub. Number AU-B-2004215647

PCT Pub. Number WO2004/076422

Priority 60/450,945 28.02.03 US

Filing date 27 February 2004

Wipo publication date 10 September 2004

Acceptance publication date 21 December 2006

International Classifications

C07D 215/26 (2006.01) Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems

Event Publications

8 September 2005 PCT application entered the National Phase

  PCT publication WO2004/076422 Priority application(s): WO2004/076422

21 December 2006 Application Accepted

  Published as AU-B-2004215647

19 April 2007 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004215648-Spiro-substituted pyrrolopyrimidines

2004215644-Pyrazolopyridine derivates